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Abstract⎯The present study was performed to investigate whether common single-nucleotide polymorphism
K121Q (rs1044498) of the ENPP1 gene is associated with the known risk factors of atherosclerosis (over-
weight, dyslipoproteinemia, hypertension, diabetes, smoking, and hypercoagulability) in persons with acute
coronary syndrome. Venous blood of 118 patients was genotyped for the polymorphism by PCR and restric-
tion fragment length polymorphism method. In patients divided into two subgroups according to their geno-
type (KK and KQ + QQ), the statistically significant differences were revealed only for plasma LDL-choles-
terol level and fibrinolytic activity. The carriers of minor allele (KQ + QQ) had lower LDL-cholesterol con-
centration and the time of fibrinolysis than the major allele homozygotes (KK). The division of patients into
subgroups according to presence or absence of some risk factors for atherosclerosis showed no statistically sig-
nificant differences between K121Q genotype distributions for any of the comparison.
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INTRODUCTION
The main cause of acute coronary syndrome (ACS)
that encompasses a spectrum of unstable coronary
artery disease from unstable angina to transmural
myocardial infarction is the formation of thrombus on
complicated atheromatous plaque. Both atherosclero-
sis and blood coagulation are the processes which
depend not only on environmental risk factors but also
on genetic features of organism. There is growing evi-
dence that genetic factors, especially single nucleotide
polymorphism (SNP) of a wide range of genes, play an
important role in the development of atherosclerosis
and its complications [1–3]. Among the genes, which
products can be involved in progression of atheroscle-
rotic lesions, the genes concerning arterial calcifica-
tion are presently of great interest [4]. It is because the
deposition of hydroxyapatite into atheromatous
plaques makes them very unstable and facilitates the
futher rupture and thrombus formation [5].
Ectonucleotide pyrophosphatase/phosphodiester-
ase 1 (ENPP1) is an enzyme with the extracellular cat-
alytic domain that is able to cleave sugar-phosphate,
phosphosulfate, pyrophosphate, and phosphodiester-
ase linkages [6]. The very important product of
ENPP1 activity is inorganic pyrophosphate (PPi) that
is known to be one of the most potent inhibitor of arte-
rial calcification [7–9]. The massive mineralization of
arteries has been shown to develop when the activity of
ENNP1 falls off and the formation of PPi is fully dis-
turbed. Generalized deposits of calcium salts in arte-
rial tissues are the most impressive feature in geneti-
cally knocked out mice (ENPP1 –/–) and in humans
who have defective ENNP1 gene [10].
There are several lines of evidence indicating the
ENPP1 contribution to the decreased insulin receptor
function [6]. Among those is the fact that one of the
most studied SNP of ENPP1 gene, known as K121Q,
is related to insulin resistance (IR) and development of
type 2 diabetes (T2D) [11, 12]. Some data suggest that
the Q121 allele is associated with an increased risk of
earlier onset of myocardial infarction [13, 14]. It seems
likely that this association is secondary to the effect of
the Q121 allele on IR and T2D, which, in turn, predis-
pose to atherosclerosis. The question remains open
whether K121Q polymorphism itself influence arte-
riosclerotic process and ACS directly, i.e. by its own
enzymatic activity which is not related to insulin
receptor inhibiting, or through the risk factors other
than IR and T2D.1 The article was translated by the authors.127
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Fig. 1. Results of ENPP1 K121Q polymorphism restriction analysis. M—molecular marker (bp—base pairs); lanes (3, 9) KK-genotype;





M 1 2 3 4 5 6 7 8 9 10The aim of the present study was to analyze the
association of the ENPP1 gene K121Q polymorphism
with well-established risk factors of atherosclerosis
such as hypercholesterolemia, hypertension, high
body mass index, diabetes, smoking, and hypercoagu-




The studied group included 118 ACS patients with
a mean age of 55.9 ± 0.89 years admitted to Sumy
Clinical Hospital no. 1. Diagnosis of ACS was estab-
lished based on clinical, electrocardiography and bio-
chemical examinations according to the recommen-
dations of WHO experts and according to the recom-
mendations of European and American cardiologic
societies [15, 16]. Patients with hereditary and innate dis-
eases, severe metabolic pathologies including a severe
form of diabetes mellitus (proliferative stage of retinopa-
thy, 2–5 stages of nephropathy, encephalopathy),
marked renal and liver failures, deficiencies of the hae-
mostatic system, oncology and systemic pathologies,
chronic heart failure of II–III stage, true cardiogenic
shock were excluded from the study group. The clini-
cal signs included generally accepted parameters
related to the risk factors for atherosclerosis and ACS:
body mass index (BMI), blood pressure (BP), the
content of lipids and lipoproteins in blood plasma, and
some indices of blood coagulation (prothrombin
time). According to these parameters, all patients were
divided into the pairs of subgroups defined by (1) BMI
(<25 kg/m2 or ≥25 kg/m2), (2) BP (non-hypertensive
or hypertensive: systolic BP > 140 mmHg, diastolic
BP > 90 mmHg), (3) low density lipoprotein choles-
terol (LDL-C) concentration (≤3.5 mmol/L or
>3.5 mmol/L), (4) diabetes mellitus type 2 (non-dia-
betic or diabetic), (5) smoking (non-smoking or smok-
ing), and (6) prothrombin time (≥9 or <9″).
The study had been previously approved by the
Ethic Committee on Medical Research of the Medical
Institute of Sumy State University. An appropriate
informed consent was obtained from all patients. Blood
sampling for genotyping was performed under sterile
conditions into 2.7 mL S-Monovette (Sarstedt, Ger-many) containing EDTA potassium salt as an antico-
agulant, samples were frozen and stored at –20°C.
Amplification and Genotyping
DNA for genotyping was extracted from the venous
blood using commercially available kits (Isogene Lab
Ltd, Russia) according to the manufacturer’s protocol.
To identify ENPPI K121Q polymorphism (rs1044498)
the polymerase chain reaction (PCR) with subsequent
restriction fragment length polymorphism (RFLP)
analysis was performed. Specific region of the ENPP1
gene was amplified using a pair of specific primers:
upstream (sense)–5'-CTGTGTTCACTTTGGACAT-
GTTG-3' and downstream (antisense)–5'-GAC-
GCTGGAAGATACCAGGCTG-3'. Primers were
provided by Metabion (Germany). PCR was per-
formed for 33 cycles in a 25 μL volume containing 50–
100 ng of DNA, 5 μL 5X PCR-buffer, 1.5 mM/L mag-
nesium sulfate, 200 μM/L of each dNTP, 15 pM/L of
each primer and 0.75U of TaqDNA polymerase
(Thermo Scientific, USA). PCR was carried out in a ter-
mocycler GeneAmpPCR System 2700 (Applied Bio-
systems, USA). Six microlitres (6 μL) of the PCR
products (238 bp) were subjected to digestion with 5U
Eco47I (AvaII) (Thermo Scientific, USA) and incu-
bated at 37°С for 18 h. When cytosine is at the position
48213 of the exon 4, Eco47I restriction enzyme pro-
duces two fragments of 148 and 90 bp in length. Sub-
stitution of cytosine for adenine prevents restriction
and the amplified fragment of the exon 4 (238 bp) can-
not be cleaved (Fig. 1). The restriction fragments were
separated by electrophoresis and analysed on an ethid-
ium bromide-stained 2.5% agarose gel visualized
using ultraviolet transillumination.
Statistical Analysis
To test if the K121Q genotypes distribution fol-
lowed Hardy-Weinberg equilibrium as well as for the
comparison of the K121Q allele and genotype fre-
quencies between different study subgroups χ2-test
was used. Since there were few individuals with the
QQ genotype, we tested whether variable means dif-
fered significantly between subjects with and without
the Q variant (KQ + QQ vs. KK). A comparison ofCYTOLOGY AND GENETICS  Vol. 52  No. 2  2018
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Table 1. Clinical characteristics of acute coronary syndrome patients with different ENPP1 gene K121Q genotype
Data are mean ± SE; n—number of subjects; HDL—igh density lipoprotein; LDL—low density lipoprotein.
Parameter KK KQ + QQ Total
P
n 79 39 118
Age, years 56.1 ± 1.17 55.5 ± 1.25 55.9 ± 0.89 0.699
Gender, M/F 62/17 30/9 92/26 0.848
BMI (M), kg/m2 28.0 ± 0.54 26.9 ± 0.6 27.6 ± 0.42 0.593
BMI (F), kg/m2 31.0 ± 1.11 32.4 ± 1.55 31.5 ± 0.9 0.467
Systolic BP, mmHg 140 ± 1.9 142 ± 3.3 141 ± 1.7 0.560
Diastolic BP, mmHg 89 ± 1.1 90 ± 1.7 89 ± 0.9 0.627
Total cholesterol, mmol/L 6.6 ± 0.16 6.0 ± 0.24 6.4 ± 0.13 0.075
LDL-cholesterol, mmol/L 4.7 ± 0.17 4.1 ± 0.26 4.5 ± 0.14 0.039
HDL-cholesterol, mmol/L 1.0 ± 0.02 1.1 ± 0.04 1.0 ± 0.02 0.062
Triglyceride, mmol/L 1.7 ± 0.1 1.8 ± 0.14 1.8 ± 0.08 0.598
Prothrombin time, s 10.4 ± 0.18 11.0 ± 0.31 10.6 ± 0.16 0.112
Thrombin time, s 17.3 ± 0.48 18.8 ± 0.8 17.8 ± 0.42 0.077
Fibrinolytic activity, s 479 ± 4.1 462 ± 6.3 473 ± 3.5 0.022
Fasting glucose, mmol/L 8.0 ± 0.32 7.8 ± 0.37 7.9 ± 0.24 0.688
Diabetes, % 23 (29.1) 7 (17.9) 30 (25.4) 0.190
Smoking, % 34 (43.0) 20 (51.3) 54 (45.8) 0.398variables between the groups of genotypes was per-
formed using two-tailed Student’s t-test. Differences
were considered statistically significant with a P-value
<0.05. All statistical analyses were performed using the
Statistical Package for Social Science program (SPSS
for Windows, version 17.0, SPSS Inc, Chicago, IL).
RESULTS
Results of the ENPP1 K121Q genotyping among
patients with ACS showed that 79 (66.9%) subjects had
KK genotype, 36 (30.5%)—KQ genotype, and 3 (2.5%)
individuals were minor allele homozygotes (QQ). Here-
with the genotype distributions of ENPP1 K121Q locus
in case group (minor allele frequency—0.181) were con-
sistent with the Hardy-Weinberg equilibrium (p > 0.05).
The known ACS risk factors include increased
BMI, hypertension, elevated levels of cholesterol and
LDL in blood plasma, diabetes mellitus, smoking, and
hypercoagulability, i.e. factors relating to atherogene-
sis and thrombi formation. In Table 1, some clinical
characteristics manifesting the abovementioned ACS
risk factors in the patients divided into two subgroups
according to their genotype (KK and KQ + QQ) are
presented.
The statistically significant differences were
revealed between these two subgroups only for LDL-
cholesterol level and fibrinolytic activity. The carriers
of minor allele (KQ + QQ) had lower LDL-choles-
terol concentration and the time of fibrinolysis than
the major allele homozygotes (KK).CYTOLOGY AND GENETICS  Vol. 52  No. 2  2018The division of patients into subgroups according
to the presence or absence of known ACS risk factors
allowed the comparative analysis of the K121Q geno-
types distribution. As shown in Table 2, statistically
significant differences were not established for any of
the comparison. The similar analysis in subjects of dif-
ferent sex also did not show any significant difference
in the ENPP1 K121Q genotype frequencies (data are
not shown).
DISCUSSION
Two important features of ENPP1 seem to be
involved in the development of arteriosclerotic lesions
and their complications. First of them is the ability of
ENPP1 to generate PPi, a major physiologic inhibitor
of calcification that exerts its effects by inhibiting
hydroxyapatite crystal growth [9, 17]. Arterial wall cal-
cification is a common pathological process that is of
great significance by itself (Mönckeberg’s sclerosis)
and can complicate atherosclerotic plaques contribut-
ing to their instability.
The second feature of ENPP1 concerns the insulin
resistance and is reported not to be related to enzyme
activity of this protein and PPi production. It is shown
that catalytic domain of ENNP1 is not involved in
inhibiting the insulin receptors because the mutation
inactivating the enzymatic activity of ENPP1 does
not impair its ability to inhibit function of insulin
receptors [18]. 
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Table 2. Distribution of genotypes by the ENPP1 gene K121Q polymorphism in subgroups of ACS patients with regards to
different disease risk factors
n—Number of subjects, BMI—body mass index, AI—atherogenicity index, PT—prothrombin time.
Genotype
BMI, n, % Blood pressure, n, %
<25 kg/m2 ≥25 kg/m2 normal elevated
KK 11 (52.4) 68 (70.1) 30 (65.2) 49 (68.1)
KQ + QQ 10 (47.6) 29 (29.9) 16 (34.8) 23 (31.9)
In total 21 97 46 72
P = 0.118 P = 0.749
Genotype
Diabetes, n, % Smoking, n, %
non-diabetic diabetic non-smokers smokers
KK 56 (63.3) 23 (76.7) 45 (70.3) 34 (63.0)
KQ + QQ 32 (36.4) 7 (23.3) 19 (29.7) 20 (37.0)
In total 88 30 64 54
P = 0.190 P = 0.398
Genotype
Blood plasma lipoproteins, n, % Blood coagulation, n, %
AI ≤ 3 AI > 3 PT ≥ 9 s PT < 9 s
KK 11 (55.0) 68 (69.4) 64 (66.7) 15 (68.2)
KQ + QQ 9 (45.0) 30 (30.6) 32 (33.3) 7 (31.8)
In total 20 98 96 22
P = 0.213 P = 0.892However, whether inhibition of insulin receptor
signaling by ENPP1 is dependent upon pyrophospha-
tase/phosphodiesterase its activity remains controver-
sial. Thus, Chin et al. [19] studying the extracellular
domain of the human ENPP1 in its native form or
with some mutations have demonstrated the func-
tional dependency between two features of ENPP1.
As shown in many clinical studies, both increased
expression and genetic polymorphism of ENPP1,
especially K121Q, are associated with IR and T2D in
humans [11, 20]. A wide range of case-control studies
have been carried out to asses the possible association
between the ENPP1 gene K121Q polymorphism and
IR, T2D, and overweight/obesity in many Caucasian
and not-Caucasian populations [6]. Although the
published results are rather contradictory, it can be
concluded that in many cases there are positive associ-
ations between Q variant of ENPP1 gene and afore-
mentioned pathological conditions. All of these con-
ditions are considered tightly pathogenetic connected
with atherosclerotic process, which is the main cause
of ACS. There is evidence suggesting that the Q allele
is associated with an increased risk of earlier onset of
myocardial infarction [13, 14]. This association may
be secondary to the effect of the Q allele on IR, T2D,
and overweight/obesity that all predispose to athero-
sclerosis.In the present study, we explored associations
between genetic variation in the ENPP1 gene and
some risk factors of atherosclerosis in patients with
ACS. Analyzing the K121Q genotypes distribution in
various subgroups of patients, we did not find any dif-
ferences in this parameter between subjects with and
without well-known risk factors for ACS. Only two
indices, LDL-cholesterol concentration and fibrino-
lytic activity, were significantly different in KK-
homozygotes and carriers of Q-allele. Both of these
parameters were lower in patients with Q-variant of
ENPP1 gene than in subjects with KK-genotype.
However, it is difficult to say whether these differences
are of any importance for pathogenesis of ACS.
CONCLUSIONS
In the present study, it was shown no differences in
ENPP1 gene K121Q genotypes distribution in the
patients with ACS divided into subgroups according to
the presence or absence of known risk factors for ath-
erosclerosis: overweight, dyslipoproteinemia, hyper-
tension, diabetes, smoking, and hypercoagulability.
Only two parameters, plasma LDL-cholesterol con-
centration and fibrinolytic activity were significantly
lower in patients with Q-variant of ENPP1 gene than
in subjects with KK-genotype.CYTOLOGY AND GENETICS  Vol. 52  No. 2  2018
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